Scientific Publications
Publications
Development of AO-176, a Next-Generation Humanized Anti-CD47 Antibody with Novel Anticancer Properties and Negligible Red Blood Cell Binding
Publication: Molecular Cancer Therapeutics. Published first online on December 26, 2019.
Authors: Robyn J. Puro, Myriam N. Bouchlaka, Ronald R. Hiebsch, Benjamin J. Capoccia, Michael J. Donio, Pamela T. Manning, William A. Frazier, Robert W. Karr, and Daniel S. Pereira
Poster Presentations
ASH Annual Meeting & Exposition 2019
Poster Presentation: Highly Differentiated Anti-CD47 Antibody AO-176, Potently Inhibits Hematologic Malignancies Alone and in Combination in Pre-Clinical Models
SITC Annual Meeting 2019
Poster Presentation: Novel SIRP Antibodies with Differentiated Characteristics for Targeting Innate Immunity in Cancer
AACR-NCI-EORTC EORTC International Conference on Molecular Targets and Cancer Therapeutics 2019
Poster Presentation: AO-176, a highly differentiated humanized anti-CD47 antibody, exhibits single-agent and combination anti-tumor efficacy with chemotherapy and targeted antibodies in preclinical models (Abstract #: B100)
AACR Annual Meeting 2019
Poster Presentation: AO-176, a normal cell sparing humanized anti-CD47 antibody
AACR Annual Meeting 2019
Poster Presentation: Evaluation of novel anti-SIRP antibodies as potential cancer therapeutics
ASH Annual Meeting & Exposition 2018
Poster Presentation: Therapeutic potential of AO-176, a next-generation humanized CD47 antibody, for hematologic malignancies
EORTC-NCI-AACR Symposium 2018
Poster Presentation: Development of AO-176, a next-generation humanized anti-CD47 antibody with novel anti-cancer properties and negligible binding to red blood cells
SITC Annual Meeting 2018
Poster Presentation: AO-176, next-generation CD47 antibody, induces immunogenic cell death
CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference 2018
Poster Presentation: AO-176, next-generation CD47 antibody, induces immunogenic cell death
AACR Annual Meeting 2018
Poster Presentation: AO-176, a humanized anti-CD47 monoclonal antibody that directly kills human tumor cells and has additional unique functional characteristics